Skip to main content
OpenTrials
Completed

NCT Number: NCT02635321

MRI and Muscle Involvement in Patients With Mutations in GMPPB

Limb girdle muscular dystrophies (LGMD) are a very heterogeneous group of muscle disorders characterized by muscle weakness and atrophy of the proximal muscles of the shoulder and pelvic girdles. LGMD is classified based on its inheritance pattern and genetic cause into more than 31 different types.

A new type - type 2T has been found. The genetic cause of type 2T is mutations in Guanosine Diphosphate (GDP)-mannose pyrophosphorylase B (GMPPB). Mutations in GMPPB can also cause Congenital muscular dystrophies (CMD). Only 41 patients with mutations in GMPPB has been reported.

In this study, the investigators examine five new cases with the LGMD phenotype. The primary aim is to examine the muscle involvement using MRI.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Limb-girdle Muscular Dystrophy Congenital, Hereditary, and Neonatal Diseases and Abnormalities Genetic Diseases, Inborn Muscular Diseases Muscular Disorders, Atrophic Muscular Dystrophies Muscular Dystrophies, Limb-Girdle Musculoskeletal Diseases Nervous System Diseases Neuromuscular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Copenhagen Neuromuscular Center

Copenhagen, 2100, Denmark

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Persons with genetically verified mutations in GMPPB

Exclusion criteria

  • All contraindications for undergoing an MRI scan

Treatment and study plan

Primary outcomes

  1. MRI scan for qualitative analysis of muscle involvement

    Time frame: One MRI scan per subject (exam lasts approximately 60 min.)

    The MRI protocol include T1-weighted brain and whole body examination. Four cross-sectional slices at shoulder, lumbar back, thigh and calf are chosen for qualitative analysis using the grading scale developed by Mercuri et al. (2007).

Secondary outcomes

  1. Muscle biopsy for biochemical investigation

    Time frame: One muscle biopsy per subject (last approximately 15 min.)

    Muscle biopsies from the tibialis anterior muscle and the deltoid muscle will be analyzed for glycosylated α-dystroglycan, merosin and GMPPB. (Concentration determined by standard biochemical analysis).

  2. 10 meter walk test

    Time frame: Exam last approximately 5 min.

    Measurement of the time it takes to walk 10 meters.

  3. Neurological examination and test of muscle strength

    Time frame: Exam last approximately 15 min.

    Muscle strength (in arms and legs) will be examined based on the Medical Research Council (MRC) scale.

  4. Questionnaires

    Time frame: Data will be collected once for patients with LGMD 2T (exam last approximately 45 min.)

    Data will be collected using Minimal mental examination (MMSE) and Fatigue Severity Scale (FSS).

  5. Heart examination

    Time frame: Exam last approximately 45 min

    Echocardiography and Electrocardiogram (ECG).

  6. Forced Vital Capacity (FVC)

    Time frame: Exam last approximately 15 min

    FVC is measured as the best of three attempts using a hand-held spirometer.

  7. Electromyography (EMG)

    Time frame: Exam last approximately 30 min

    EMG is used for measuring nerve conducting velocity and neuromuscular activity.

Sponsors and collaborators

Lead sponsor

Rigshospitalet, Denmark

Other

Registry information

Important dates

Study start
2015
Primary completion
2016
Study completion
2016
First posted
Dec 18, 2015
Registry last updated
Apr 6, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.